<DOC>
	<DOCNO>NCT00486876</DOCNO>
	<brief_summary>The primary objective study evaluate clinical safety tolerability ass efficacy 100 mg , 200 mg , 300 mg BID dextofisopam compare placebo female outpatient diarrhea-predominant alternate irritable bowel syndrome ( IBS ) .</brief_summary>
	<brief_title>A Study 3 Doses Dextofisopam Females With Irritable Bowel Syndrome</brief_title>
	<detailed_description>This double-blind , randomize , placebo-controlled Phase 2b study safety , tolerability , efficacy 100 , 200 300 mg BID dextofisopam female patient suffer diarrhea-predominant alternating-Irritable Bowel Syndrome . ( d-IBS a-IBS . ) Approximately 120 patient enrol 4 arm study conduct 70 clinical site USA . The patient ; stratify diagnosis . Outpatient female , 18 65 year old enrol study diagnose d-IBS a-IBS screen 17 day prior enrollment ( include colonoscopy do within last 5 year ) find organic disease might cause complaint abdominal pain discomfort start associated change stool frequency form and/or improve defecation . Patients instruct take 3 capsule blind study drug twice day mouth record interactive voice response system ( IVRS ) change symptom . Patients meet Inclusion Exclusion criterion evaluate baseline ( one day prior take study drug ) include laboratory determination include pregnancy test woman childbearing potential , vital sign , electrocardiogram ( ECG ) , record adverse event ( AE 's ) filling IBS Quality Life Questionnaire ( IBSQOL ) , Work Productivity Activity Impairment Questionnaire-IBS Version ( WPAI : IBS ) Hospital l Anxiety Depression Questionnaire ( HAD ) . Enrolled patient 12 week double-blind treatment follow 28 day post treatment period . Symptoms record daily . Patients visit investigate site week 4 , 8 12 baseline visit procedure perform baseline repeat A post treatment visit occur 28 day discontinue study drug . Vital sign , AE 's , concomitant medication daily weekly symptom assessment via IVRS record .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Tofisopam</mesh_term>
	<criteria>Ages Eligible Study : 18 Years 65 Years , Genders Eligible Study : Female 1 . Outpatient postmenopausal pregnant females,18 65 year old 2 . Irritable bowel syndrome , meet Rome III criterion IBS diarrheapredominant alternate subtype 3 . Able give inform consent 4 Willingness make daily call touchtone telephone 1 . Clinically significant abnormality screening test . 2 . Use investigational drug within 30 day screen visit . 3 . Serious underlying disease , include psychiatric disorder current history condition affect bowel habit 4 . Previous treatment tofisopam Related drug . 5 . History presence clinically significant medical disease might compromise study detrimental patient , 6 . Subject exclusively constipationpredominant IBS .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Irritable bowel syndrome</keyword>
	<keyword>Diarrhea predominant Irritable Bowel Syndrome</keyword>
	<keyword>Alternating Irritable Bowel Syndrome</keyword>
</DOC>